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CHAPTER 10  ■  MUSCLE 
 
 
     
Robert L. Hall, DVM, PhD  





Muscle diseases characterized by degeneration, necrosis, or inflammation with 
degeneration/necrosis may be detected with clinical chemistry techniques. The common 
feature of these conditions is disruption of muscle cell membranes and release of 
enzymes and cytoplasmic contents into surrounding blood and lymph. Muscular atrophy 
and neoplastic conditions not associated with cell membrane disruption usually do not 
cause changes in standard clinical chemistry tests. 
I. Serum enzymes of muscle origin 
A. Creatine kinase (CK) 
1. CK is critical to muscle energy production. CK makes adenosine triphosphate  
    (ATP) available for muscle contraction by catalyzing the transfer of a high- 
    energy phosphate bond from creatine phosphate to adenosine diphosphate  
    (ADP). CK also catalyzes the reverse reaction when muscles are at rest. Muscle  
    cells contain eight times more creatine phosphate than ATP, thereby  
    providing a reservoir of high-energy phosphate bonds for contraction. 
2. CK is primarily a cytosolic enzyme with highest activity in skeletal muscle,  
cardiac muscle, and brain. Liver has negligible CK activity.   
3. CK is one of the most organ specific clinical enzymes, as most serum CK  
    activity is of muscle origin. 
4. CK is a dimeric enzyme with two subunits designated B for brain and M for  
muscle. Three principal isoenzyme types exist: CK-BB (CK1), CK-MB (CK2), 
and CK-MM (CK3). 
 a. CK isoenzymes can be separated electrophoretically, and the proportion 
     of each determined. CK-BB is the most anodal. 
 b. CK isoenzymes may also be separated by species-specific 
      immunological methods or by ion-exchange chromatography. 
 c. CK-BB is present in brain, peripheral nerves, cerebrospinal fluid, and 
     viscera. 
 d. CK-MB is present in cardiac muscle with relatively low activity in 
     other tissues. 
 e. CK-MM is present in both skeletal and cardiac muscle. 
 f. CK activity in serum is mostly CK-MM, followed by CK-BB, and very 
    little, if any, CK-MB. 
 g. CK isoenzyme analysis has not been very informative in veterinary 
     medicine and is rarely used in a clinical setting. 
 5. Erythrocytes contain very little CK, but enzymes and intermediates released  
                from erythrocytes may affect assay reactions, causing falsely increased  
                activity when hemolysis is present.  Hemolyzed serum specimens are  
    unsatisfactory for determination of CK activity. 
6. Dilution of serum samples to reduce CK activity to an acceptable range for  
    measurement may paradoxically falsely increase enzymatic activity due to 
   dilution of naturally occurring CK inhibitors. 
7. Serum CK activity in healthy dogs varies with age and breed.  
a. CK activity decreases with age; pups can have much higher CK activity 
     than adult dogs.  
b. Adult levels of CK activity are achieved by 7-12 months of age.  
c. Small breeds of dogs tend to have higher activities. 
8. Plasma CK half-life is short (< 3 hours in dogs, ~ 4 hours in cattle, < 2 hours 
    in horses).  
9. Specimens analyzed for CK activity should be processed quickly. 
a. Reports vary concerning stability of CK activity in serum and plasma.  
b. CK activity may diminish if a prolonged delay occurs between 
    obtaining and analyzing the serum specimen (e.g., transport via mail 
    from the veterinary hospital to the laboratory).  
c. If CK analysis must be delayed beyond 12 hours, serum or plasma  
    should be frozen (-20°C) to minimize loss of activity.  
d. Loss of activity can be partially reversed through the use of  
    reducing agents in the assay system. 
e. Serum CK activity is higher than plasma CK activity in the dog, and 
    perhaps other species, due to release of CK from platelets during clot 
    formation.  
B. Aspartate aminotransferase (AST) (see Chapter 7) 
1. AST catalyzes the reversible transamination of L-aspartate and 2-oxoglutarate 
    to oxaloacetate and glutamate.  Oxaloacetate can enter the Krebs cycle.  The 
    enzyme was previously known as serum glutamic oxaloacetic transaminase 
    (SGOT). 
2. AST has cytosolic and mitochondrial isoenzymes, and AST activity is present 
    in almost all cells, including red blood cells. 
3. Serum AST activity is tissue-nonspecific, but muscle and liver are the major 
    sources. 
4. Plasma AST half-life is < 12 hours in cats, ~12 hours in dogs, ~18 hours in 
    swine, and probably longer in horses and cattle. 
5. Plasma AST half-life is longer than plasma CK half-life. 
6. AST is relatively stable at room, refrigerator, and freezer temperatures.  
7. Separate serum or plasma from cells immediately as imperceptible hemolysis 
    may falsely increase AST activity. 
C. Alanine aminotransferase (ALT) (see Chapter 7) 
1. ALT catalyses the reversible transamination of L-alanine and 2-oxoglutarate to  
    pyruvate and glutamate.  Pyruvate can be used for gluconeogenesis or enter the 
    Krebs cycle.  The enzyme was previously known as serum glutamic pyruvic 
    transaminase (SGPT). 
2. ALT is primarily a cytosolic enzyme considered liver-specific in dog and cat; 
    however, increases in ALT activity have been reported with muscle diseases 
    such as X-linked muscular dystrophy or toxic myopathies. 
3. ALT has been used as a muscle-specific enzyme in large animals because  
    hepatic ALT activity in large animals is very low. Increased activity has been 
    reported in myopathies of lambs, pigs, and horses.  
4. Plasma ALT half-life in dogs is considered ~2.5 days.  Plasma ALT half-life is 
    likely greater than that for AST or CK in most species. 
D. Lactate dehydrogenase (LDH) 
1. LDH is a cytosolic enzyme present in all cells, and therefore all tissues, that 
    catalyzes the reversible conversion of L-lactate to pyruvate.  
2. Muscle, liver, and erythrocytes are usually the sources of high LDH activity  
    in serum. 
3. LDH is less useful than CK and AST for determining muscle damage because 
    it lacks tissue specificity and is significantly affected by even mild hemolysis. 
4. LDH is a tetrameric enzyme made up of two subunits, H and M, to form five 
    isoenzymes, LDH1 (H4), LDH2 (H3M1), LDH3 (H2M2), LDH4 (H1M3), and 
    LDH5 (M4).  In general, isoenzymes with mostly H subunits (LDH1 and 
    LDH2) predominate in aerobic tissue and those with mostly M subunits 
    predominate in anaerobic tissue. 
 a. LDH isoenzymes can be separated electrophoretically, and the 
    proportion of each determined. LDH1 (H4) is the most anodal. 
 b. LDH1 (H4) is heat stable; LDH2-5 are inactivated in serum when heated 
     at 65° C for 30 minutes. 
 c. LDH1 (H4) is the principal isoenzyme in cardiac muscle and kidney. 
 d. LDH5 (M4) is the principal isoenzyme in skeletal muscle and 
     erythrocytes. 
 e. Liver contains primarily LDH4 and LDH5 (H1M3 and M4) in many 
     species, but the liver isoenzyme profile for cattle and sheep is more 
     similar to heart. 
 f. All tissues contain variable amounts of the five LDH isoenzymes, and 
    even with electrophoretic separation, the tissue source of increased 
    serum LDH activity is often uncertain. 
5. Separate serum or plasma from cells immediately as imperceptible hemolysis 
    may falsely increase LDH activity. 
6. LDH is unstable at freezer temperatures (-20°C), more stable at refrigerator 
    temperatures (4°C). 
7. Plasma LDH half-life varies for each isoenzyme with LDH1 (H4) being longest 
    and LDH5 (M4) being shortest.  
E. Aldolase 
1. Aldolase in muscle (also called aldolase A) is a cytosolic enzyme that catalyzes 
    the cleaving of fructose-1,6-bisphosphate to form glyceraldehyde 3-phosphate 
    and dihydroxyacetone phosphate in the glycolytic utilization of fructose for 
    energy. 
2. Aldolase has been used to investigate skeletal muscle disorders, but isoenzymes 
    exist in multiple tissues, including liver and heart. 
3. Aldolase is generally considered inferior to CK for diagnosis of skeletal  
    muscle disorders because CK has better diagnostic sensitivity and greater  
    ease of measurement in the laboratory.   
 
II. Diagnostic significance of CK, AST, and LDH 
A. Increased serum CK, AST and LDH activities occur with degenerative or  
    necrotizing muscle injury. Diseases associated with increased serum activity of  
    these enzymes are listed in Table 10.1. 
1. CK is the most sensitive serum enzyme indicator of striated muscle damage. 
 a. CK is the enzyme of choice to detect skeletal muscle damage. 
 b. Serum CK activity increases within 4-6 hours after muscle injury and 
     typically reaches maximum levels in 6-12 hours. 
 c. Serum CK activity returns to the reference interval within 48-72 hours 
     once muscle injury abates. 
 d. Persistently high serum CK activity indicates continued muscle injury. 
 e. The magnitude of increased serum CK activity generally correlates with 
     extent of muscle injury, but exceptions occur. Only marked (e.g., 
     >5,000 IU/L) or moderate but persistent increases (e.g., >2000 IU/L) 
     are considered clinically significant. 
 f. Minor increases of serum CK activity are considered more significant in 
    cats because of smaller muscle mass and comparatively low CK activity 
    in cat muscle.  However, anorexic cats can exhibit increased serum CK 
    activity in the absence of diseases directly affecting muscle.   
2. Serum AST activity increases slower than serum activities of CK and LDH 
     following muscle injury; increased serum AST activity may persist several 
    days after muscle injury abates. 
3. Serum LDH activity increases following muscle injury are less apparent than 
    those for CK and AST and more difficult to assess because of the broad tissue 
    distribution of LDH. 
B. Serum CK and LDH isoenzymes have some tissue specificity. 
1. Serum CK-MM and LDH5 (M4) activities increase in greater proportion 
    following skeletal muscle injury. 
2. Serum CK-MB and LDH1 (H4) activities increase in greater proportion 
    following cardiac muscle injury. However, CK-MB has not proven effective for 
   diagnosing equine cardiac muscle injury. 
3. Serum LDH1 (H4) activity increases in hemolytic disease but also 
    hemolyzed samples. 
4. In general, determination of serum CK and LDH isoenzyme patterns have not  
    proven valuable or practical for clinical veterinary medicine.  Cardiac troponins 
    are proving to be more sensitive, specific, and practical for assessing cardiac 
    muscle injury. 
C. Serum CK activity can be affected by minor muscle injuries unrelated to primary 
     muscle disease. 
1. Placement of electrodes for electromyography increases serum CK activity  
    but usually not above the reference interval. 
2. Intramuscular injections increase serum CK activity. Irritating drugs (e.g., 
    ketamine) or drug vehicles can cause dramatic increases lasting up to 1 week. 
3. Traumatic venipuncture, even in the absence of hemolysis, can increase  
    serum CK activity. Sample contamination with perivenous connective tissue or 
    muscle can occur. 
4. Strenuous exercise in dogs and horses increases serum CK and LDH activities.  
a. Rarely more than three-fold baseline after light exercise. 
b. Physical training minimizes post-exercise increases. 
5. Animal shipping may cause increased serum CK activity. 
D. Cerebrospinal fluid (CSF) CK activity originates from the brain and may increase  
     with central nervous system (CNS) disease.  
1. Increased CSF-CK activity does not affect serum CK activity.  
2. Increased serum CK activity associated with CNS disease likely originates  
    from injury to muscle cells during convulsions (e.g., involuntary muscle 
    contractions or contusions) or prolonged recumbency. 
E.  Increased serum LDH activity has been associated with canine lymphoma. 
F.  Lymphoma in cattle is associated with high serum LDH activity in about 70% of  
     affected animals. 
1. Serum LDH activities overlap between clinically healthy and affected cattle.  
2. Serum LDH activity is not elevated for cattle with persistent lymphocytosis. 
G. CK, AST, and LDH activities are used to diagnose skeletal muscle disease in 
     birds.  
1. As in mammals, serum CK activity is the most muscle-specific indicator.  
2. Hemolysis markedly increases avian serum LDH activity.  
 
III. Other laboratory findings in muscle disease 
A. Troponins 
1. Troponins are globular proteins bound to tropomyosin that help modulate the 
     interaction between actin and myosin within the myofibril of striated muscle. 
 a. Three troponin proteins form a regulatory complex: troponin I, 
     troponin T, and troponin C. 
 b. Troponin I and T have genetically distinct cardiac isoforms and are 
     therefore useful for evaluating cardiac muscle injury. 
 c. Cardiac troponins I and T (cTnI and cTnT) are considered the markers 
     of choice for acute cardiac injury in humans, replacing CK-MB. 
 d. cTnI and cTnT are highly conserved in mammalian species and many 
     human immunoassays cross-react with cardiac troponins in animals. 
 e. Many functional assay systems exist for cTnI.  The cTnT assay is 
     limited to one vendor and less available. 
 f. There is no clear diagnostic advantage measuring both cTnI and cTnT. 
2. Cardiac troponins are released into blood by degenerating/necrotic cardiac 
    muscle cells. 
3. Serum cardiac troponin concentrations are normally very low, and increases 
    are apparent within a few hours of cardiac muscle injury. 
4. Cardiac troponins have short half-lives (hours) so serum levels decrease 
    quickly (1 or 2 days) unless cardiac muscle injury is ongoing. 
5. Increased serum cardiac troponin concentrations have also been observed with 
    strenuous exercise in horses and renal failure. 
B. Natriuretic peptides 
 1. Two natriuretic peptides, atrial or A-type (ANP) and brain or B-type (BNP) 
          have been studied as markers for cardiac muscle function/dysfunction. 
 2. Natriuretic peptides are released as prohormones from cardiac muscle in 
          response to mechanical stress or cardiac muscle stretching, most often due to 
          increased pressure. 
 3. The prohormones are cleaved into inactive N-terminal fragments (NTproANP 
     or NTproBNP) and active C-terminal fragments (ANP and BNP). 
 4. Active ANP and BNP contribute to cardiovascular homeostasis by inhibiting 
          the renin-angiotensin-aldosterone system, promoting vasodilatation, increasing 
          natriuresis and diuresis, and decreasing arterial blood pressure. 
 5. Assays have been developed for the inactive N-terminal fragments and active 
          C-terminal fragments. 
  a. BNP and NTproBNP are used in human medicine as sensitive but 
                      nonspecific markers for congestive heart failure. 
  b. Human BNP and NTproBNP assays do not cross-react well with animal 
      peptides so development of species-specific assays has limited use of 
      these markers until recently. 
  c. Half-lives for the inactive active fragments may be longer than those for 
      active fragments, making the inactive fragments (NTproANP and 
      NTproBNP) more attractive as potential markers of heart disease. 
C. Myoglobin  
1. Myoglobin is a heme protein responsible for transporting and storing oxygen 
    within muscle cells. Myoglobin is normally absent in serum. 
2. Myoglobin is considered a specific and sensitive indicator of muscle necrosis.  
a. Myoglobin released from muscle enters blood immediately.  
b. CK and AST first enter lymph, delaying increased serum activity. 
c. Serum myoglobin falls rapidly once muscle injury abates. 
3. Myoglobin is a low molecular weight monomer that, unlike hemoglobin, does 
    not bind significantly to plasma proteins. 
4. Myoglobin readily passes through the glomerulus, and plasma may not 
    become discolored. 
5. Both myoglobin and hemoglobin cause a positive urine occult blood reaction 
   on urinalysis test strips (see Chapter 9) and pink to red to brown urine 
   depending on concentration and degradation/oxidation. 
 a. An ammonium sulfate precipitation test to differentiate myoglobin from 
     hemoglobin is unreliable (in theory, hemoglobin precipitates in an 80% 
     ammonium sulfate solution, but myoglobin does not.) 
 b. Myoglobinuria is typically associated with other evidence of muscle 
     injury, normal plasma color, and normal hematocrit. 
 c. Hemoglobinuria is typically associated with other evidence of 
     hemolysis (e.g., low hematocrit), pink to red plasma, and no supporting 
     evidence for muscle injury. 
6. Myoglobin can be measured in serum or urine by a variety of immunoassays 
    but they are used infrequently in clinical veterinary medicine. 
D. Potassium  
1. Intracellular fluid contains much more potassium than extracellular fluid. 
2. Degeneration or necrosis of a large muscle mass may release enough  
    potassium to cause hyperkalemia. 
a. Correlation between hyperkalemia and increased muscle serum 
    enzyme activity may be poor.  
b. Hyperkalemia is more commonly associated with disorders of acid-base 
    and electrolyte balance (see Chapter 5).  
3. Hyperkalemic periodic paralysis in Quarter horses is due to skeletal muscle  
    sodium channel defects and often results in hyperkalemia.  
a. Hyperkalemia is present during or immediately following clinical signs  
    of disease (e.g., muscle fasciculations, collapse) but not between  
    episodes.  
b. Serum CK activity may be mildly increased or within the reference  
    interval. 
4. Hypokalemic polymyopathy may occur in cats with chronic renal failure or fed 
    acidifying diets. Hypokalemia and increased serum CK activity are typical.  
E. Lactate (see Chapters 5 and 6) 
1. Lactate is a byproduct of anaerobic glycolysis produced primarily by skeletal 
    muscle, erythrocytes, brain, skin, and renal medulla.  
2. Blood lactate concentration reflects a balance between lactate production, 
    metabolism by the liver (used for gluconeogenesis), and elimination in urine. 
3. Plasma lactate increases markedly after exercise in dogs with exercise-induced 
    mitochondrial and lipid storage myopathies and Labrador Retrievers with 
    hereditary myopathy. 
4. Meticulous sample acquisition and handling are essential for lactate analysis in 
    whole blood or plasma. 
 a. Blood should be collected into tubes containing sodium fluoride and 
     potassium oxalate, chilled, and centrifuged within 15 minutes.  Fluoride 
     inhibits anaerobic glycolysis and lactate production by erythrocytes. 
 b. Blood lactate can increase if the patient struggles during venipuncture 
     (muscle activity) or if the vein is held off for a prolonged period 
     (venous stasis and local hypoxia). 
 c. Blood lactate can also increase after a meal. 
F. Dystrophin and muscular dystrophy 
1. Dystrophin is a cytoplasmic cytoskeleton protein that helps reinforce the 
    sarcolemma and is part of a transmembrane protein complex that connects the 
    muscle fiber to extracellular matrix.  
2. An X-linked inherited deficiency of dystrophin causing muscular dystrophy has 
    been described in dogs and cats.  The disorder is characterized by progressive 
    muscle degeneration/necrosis, with hypertrophy of some muscle groups, and 
    increased serum muscle enzyme activities. 
3. Dystrophin in muscle can assessed by immunocytochemistry or immunoblot 
    techniques.  
4. Cases of canine muscular dystrophy without dystrophin deficiency have been  
    reported. 
G. Acetylcholine receptor antibodies and myasthenia gravis 
1. Immunoprecipitation tests are used to detect circulating autoantibodies to 
    acetylcholine receptors in dogs and cats with immune-mediated myasthenia 
    gravis. 
2. Antibodies are absent in congenital (non-immune-mediated) myasthenia gravis. 
H. Erythrocyte glutathione peroxidase activity and selenium deficiency 
1. Decreased erythrocyte glutathione peroxidase activity is associated with 
    selenium deficiency because selenium is a cofactor for the enzyme.  
2. Serum vitamin E and selenium concentrations can also be measured. 
      I. Thiamine (vitamin B1) deficiency 
 1. Although infrequent to rare, thiamine deficiency may cause myocardial  
    necrosis as well as CNS disease. 




Table 10.1 Diseases with high serum enzyme activity (CK, LDH, AST) of muscle origin 




      Bacterial  
Clostridial myositis 
Immune-mediated Streptococcus equi infections 
Leptospira icterohaemorrhagiae 
 Pasteurella multocida myositis (cats) 
Staphylococcal and streptococcal myositis (dogs) 
       Parasitic 
Hepatozoon canis 
Neospora caninum 




Viral   
Blue tongue 
Bovine ephemeral fever 
Bovine virus diarrhea 
Equine herpesvirus 1 
Equine infectious anemia 
Equine influenza virus A2 
Malignant catarrhal fever 
Noninfectious 
Dermatomyositis (dogs) 
Eosinophilic myositis (dogs, cattle) 
Immune-mediated polymyositis (dogs and cats) 
Masticatory muscle myositis (dogs) 
Traumatic myopathies 
Accidental 




Prolonged recumbency of large animals (downer animals) 
Intramuscular injections of irritating substances 
Gastrocnemius rupture (horses) 
Secondary to joint diseases 
Tourniquet syndrome 
Degenerative myopathies 
Inherited or congenital 
Lysosomal alpha-1,4-glucosidase deficiency (dogs, Shorthorn and Brahman  
       cattle) 
Debranching enzyme deficiency (dogs and foals) 
      Hyperkalemic periodic paralysis (horses) 
      Mitochondrial myopathy  
Decreased cytochrome C oxidase (sheep dogs) 
Respiratory chain defect (Arabian horses) 
Muscular dystrophy (cattle, sheep, dogs, cats, chickens) 
Myophosphorylase deficiency (cattle) 
Myotonia (dogs, goats, horses) 
 Chloride-channel myotonia (goats) 
Phosphofructokinase deficiency (English Springer Spaniels)  
Lysosomal alpha-polysaccharide storage myopathy (horses) 
Metabolic or unknown cause 
Acquired equine motor neuron disease 
Anesthesia (horses, swine) 
Canine exertional rhabdomyolysis in racing greyhounds 
Capture myopathy 
Equine rhabdomyolysis (paralytic myoglobinuria, azoturia, Monday morning  
     disease, tying-up syndrome) 
Hyperadrenocorticism (dogs, horses) 
Hypokalemic polymyopathy (cats) 
Hypothyroidism (dogs, horses) 
Malignant hyperthermia (swine, dogs) 
Porcine stress syndrome 
Toxic  
Blister beetle toxicosis 
Bracken fern (myocardial necrosis in horses)  
Cassia sp. (coffee weed, castor bean, sicklepod) toxicosis (cattle, horse) 
Copper poisoning (sheep) 
Gossypol toxicosis (cattle, horse) 
Horsetail (Equisetum arvense) (horses) 
Ionophore-induced myocardial and skeletal muscle degeneration from  
 monensin, lasalocid, maduramicin, or salinomysin (horse, ruminants,  




Thiamine (vitamin B1) deficiency 
 Destruction if thiamine in heat (> 100°C) processed diets (dogs, cats) 
            Excessive thiaminase ingestion 
  Bracken fern (horses) 
  Horsetail (Equisetum arvense) (horses) 
Vitamin E / selenium deficiency (calves, lambs, yearling cattle, foals, kids,  
swine, dogs, ostriches) 
Ischemic myopathies 
 Aortic thrombosis (cats) 
Bacterial endocarditis 
Dirofilariasis 
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